ArticleNeuropathology and applied neurobiology2026
Commitment to Myogenic Differentiation Significantly Aggravates the RNA Phenotype in Myotonic Dystrophy Type 1.
Article in Neuropathology and applied neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsMyotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder classified as a spliceopathy, caused by a (CTG)n repeat expansion in the 3' UTR of the DMPK gene. The expansion in DMPK transcripts sequesters key splicing regulators of the MBNL family, leading to dysregulated alternative splicing. DM1 presents heterogeneous symptoms, with prevalent muscle weakness and myotonia, highlighting the need to understand its impact on the myogenesis process in more detail. This study aims to understand the impact of myotonic dystrophy type 1 (DM1) on myogenesis by investigating RNA expression during the differentiation of DM1 and isogenic CRISPR/Cas9-corrected DM∆ myoblast cell lines into myotubes.
methodsRNA samples were collected at various stages of myogenesis from DM1 and control DM∆ myoblast cell lines. Gene expression patterns and alternative splicing signatures were analysed using high-coverage sequencing.
resultsProliferating myoblasts exhibited a mild phenotype, with only a few differentially expressed genes and aberrant splicing events. However, upon commitment to fusion in differentiating cultures, there was a marked increase in differentially expressed genes between DM1 and corrected cells, particularly those related to muscle function and ion transport. Notably, aberrant alternative splicing, enriched for MBNL1 binding motifs, aggravated during differentiation, affecting genes associated with muscle organization, contraction and cell junctions.
conclusionsThese findings highlight that the disturbance of myogenesis becomes particularly evident upon commitment to differentiation, emphasising the critical role of differentiation- and MBNL1-dependent splicing throughout myogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.